

MyoD, which is an inhibitor of the CDK4. CDK4 is one of a number of cyclin-dependent kinases which control progression through the cell cycle through their ability to phosphorylate particular substrates at the correct phase of the cell cycle. CDK4 has been shown to be involved in cell cycle control through its ability to regulate the activity of the retinoblastoma protein, pRb, an activator of genes essential for cell division.

Inhibitors of the cyclin-dependent kinases, such as the peptides described in this invention, prevent cell cycle progression and induce cells to exit the cell cycle into the Go state. The peptides described in this invention prevent the phosphorylation of pRb by CDK4, an obligate step for entry into the cell cycle. Osteosarcomas and habdosarcomas are two types of tumors known to over-express pRb. The inhibitor described in this invention may be useful in treating these cancers or other diseases which have been specifically linked to over-expression of active pRb.

#### Applications

Method to treat proliferative disorders, including cancer.

Anti-proliferative therapeutics.

Research tool to study the cell cycle.

**Advantages:** Expression of this peptide either as a fusion protein with GST or GFP results in the cessation of cell growth.

#### Market

An estimated 1,444,920 new cancer diagnoses in the U.S. in 2007.

600,000 deaths caused by cancer in the U.S. in 2006.

Cancer is the second leading cause of death in the United States.

It is estimated that market for cancer drugs would double to \$50 billion a year in 2010 from \$25 billion in 2006.

**Development Status:** The technology is currently in the pre-clinical stage of development.

**Inventors:** Bruce M. Paterson and Jian-min Zhang (NCI).

**Publication:** JM Zhang, *et al.* Coupling of the cell cycle and myogenesis through the cyclin D1-dependent interaction of MyoD with cdk4. EMBO J. 1999 Feb 15;18(4):926-933.

**Patent Status:** U.S. Patent Application No. 10/018,964 filed 11 Apr 2002, claiming priority to 18 Jun 1999 (HHS Reference No. E-153-1998/0-US-03).

**Licensing Status:** Available for exclusive or non-exclusive licensing.

**Licensing Contact:** Jennifer Wong; 301/435-4633; [wongje@mail.nih.gov](mailto:wongje@mail.nih.gov).

**Collaborative Research Opportunity:** The National Cancer Institute's

Laboratory of Biochemistry and Molecular Biology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the described cdk4 inhibitory peptides or equivalent peptide mimetics. Please contact John D. Hewes, PhD at 301-435-3121 or [hewesj@mail.nih.gov](mailto:hewesj@mail.nih.gov) for more information.

Dated: September 6, 2007.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. E7-18192 Filed 9-14-07; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Neurological Disorders And Stroke; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Board of Scientific Counselors, National Institute of Neurological Disorders and Stroke.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute of Neurological Disorders And Stroke, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** Board of Scientific Counselors, National Institute of Neurological Disorders and Stroke.

**Date:** September 30-October 2, 2007.

**Time:** September 30, 2007, 7 p.m. to 10 p.m.

**Agenda:** To review and evaluate personal qualifications and performance, and competence of individual investigators.

**Place:** Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Susquehanna/Severn Room, Bethesda, MD 20814.

**Time:** October 1, 2007, 8:30 a.m. to 6:30 p.m.

**Agenda:** To review and evaluate personal qualifications and performance, and competence of individual investigators.

**Place:** National Institutes of Health, Neuroscience Center, 6001 Executive

Boulevard, Conference Room A, Rockville, MD 20852.

**Time:** October 2, 2007, 8:30 a.m. to 12 p.m.

**Agenda:** To review and evaluate personal qualifications and performance, and competence of individual investigators.

**Place:** Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Susquehanna/Severn Room, Bethesda, MD 20814.

**Contact Person:** Alan P. Koretsky, PhD, Scientific Director, Division of Intramural Research, National Institute Of Neurological Disorders & Stroke, NIH, 35 Convent Drive, Room 6A 908, Bethesda, MD 20892, 301-435-2232, [koretskya@ninds.nih.gov](mailto:koretskya@ninds.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS).

Dated: September 6, 2007.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 07-4566 Filed 9-14-07; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institutes of Nursing Research; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Council for Nursing Research.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who play to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Advisory Council for Nursing Research.

**Date:** September 25-26, 2007.

**Open:** September 25, 2007, 1 p.m. to 5 p.m.